| Literature DB >> 28611952 |
Irina Miralda1, Silvia M Uriarte1,2, Kenneth R McLeish2,3.
Abstract
Exposure to pro-inflammatory cytokines, chemokines, mitochondrial contents, and bacterial and viral products induces neutrophils to transition from a basal state into a primed one, which is currently defined as an enhanced response to activating stimuli. Although, typically associated with enhanced generation of reactive oxygen species (ROS) by the NADPH oxidase, primed neutrophils show enhanced responsiveness of exocytosis, NET formation, and chemotaxis. Phenotypic changes associated with priming also include activation of a subset of functions, including adhesion, transcription, metabolism, and rate of apoptosis. This review summarizes the breadth of phenotypic changes associated with priming and reviews current knowledge of the molecular mechanisms behind those changes. We conclude that the current definition of priming is too restrictive. Priming represents a combination of enhanced responsiveness and activated functions that regulate both adaptive and innate immune responses.Entities:
Keywords: apoptosis; chemotaxis; cytokines; exocytosis; neutrophils; phagocytosis; priming; respiratory burst
Mesh:
Substances:
Year: 2017 PMID: 28611952 PMCID: PMC5447094 DOI: 10.3389/fcimb.2017.00217
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Figure 1Priming-associated phenotypic changes and their effect on neutrophil functional responses. Neutrophils in circulating blood are in a resting state, characterized by a round morphology, non-adherence, minimal transcriptional activity, and a limited capacity to respond to activating stimuli. Microbial entry into tissues or tissue injury induces local immune cells to release pro-inflammatory cytokines that modify endothelial cell adhesion molecule profile and enter the bloodstream to begin priming neutrophils. Upon exposure to these priming agents, neutrophils undergo an increase in enzymatic and transcriptional activity that results in activation and synthesis of inflammatory mediators and enzymes that mediate downstream phenotypic and functional changes. Immediately, neutrophils begin to change their adhesion receptor pattern by shedding selectins, fusing secretory vesicles with the plasma membrane which leads to increased integrin expression, and a rapid increase in the gene expression of several surface receptors that allows newly primed cells to more rapidly adhere to endothelial cells (A). This phenotypic change coupled with the release of granules containing matrix metalloproteases, promotes neutrophil migration into inflamed tissues (B). The priming process continues when neutrophils bind to extracellular matrix proteins (C). Binding of neutrophil extracellular matrix receptors leads to an increase in actin polymerization, available receptors from secretory vesicle degranulation, and intracellular signaling that results in enhanced chemotaxis and chemokinesis (D). When primed neutrophils encounter bacteria, their phagocytic capacity is increased due to the upregulation in the number and affinity of receptors on the plasma membrane (F). By then, ROS production, granule release (G), and NET formation (E) have been primed to augment microbicidal activities. Finally, priming prolongs neutrophil lifespan by activating anti-apoptotic signal transduction pathways and transcription factors that decrease transcription of pro-apoptotic factors (H).
Known priming agents' capacity to induce phenotypic changes in neutrophils.
| Chemoattractants | fMLF | ↑ (El Azreq et al., | ↑ Halpert et al., | ↑ Richardson and Patel, | ↑Uriarte et al., | ? | No change Klein et al., | ↑Browning et al., |
| C5a | ↑ Jagels et al., | ↑ Halpert et al., | ↑/↓ Morris et al., | ↑ DiScipio et al., | ? | ↓ Perianayagam et al., | ↑ Finsterbusch et al., | |
| LTB4 | ↑ Eun et al., | ↑ Afonso et al., | ↑ Mancuso et al., | ↑ Kannan, | ? | ↓ Klein et al., | ↑ Finsterbusch et al., | |
| PAF | ↑ Kulkarni et al., | ↑ Shalit et al., | ↑ Rosales and Brown, | ↑ Andreasson et al., | ? | ↓ Khreiss et al., | ↑ Aquino et al., | |
| Cytokines | TNF-α | ↑ Bouaouina et al., | ↑ Montecucco et al., | ↑ Della Bianca et al., | ↑ McLeish et al., | ↑ Hazeldine et al., | ↑/↓ Murray et al., | ↑ Bauldry et al., |
| GM-CSF | ↑ Yuo et al., | ↑ Cheng et al., | ↑ Kletter et al., | ↑ Kowanko et al., | ↑ Yousefi et al., | ↓ Klein et al., | ↑ DiPersio et al., | |
| IFN-γ | ↑ Klebanoff et al., | ↓ Aas et al., | ↑ Melby et al., | ↑ Cassatella et al., | ? | ↑ Perussia et al., | ↑ Humphreys et al., | |
| IL-1β | ↑ Brandolini et al., | ↑ Brandolini et al., | ? | ↑ Brandolini et al., | ? | ? | ? | |
| IL-8 | ↑ Detmers et al., | ↑ Baggiolini and Clark-Lewis, | ↑ Richardson and Patel, | ↑ Baggiolini and Clark-Lewis, | ↑ Hazeldine et al., | ↓ Acorci et al., | ? | |
| IL-15 | ? | ↑ Mastroianni et al., | ↑ Musso et al., | ? | ? | ↓ Mastroianni et al., | ↑ Musso et al., | |
| IL-18 | ↑ Wyman et al., | ? | ? | ? | ? | ↑ Wyman et al., | ↑ Jablonska et al., | |
| IL-33 | ? | ↑ Le et al., | ↑ Lan et al., | ? | ? | ? | ? | |
| Adiponectin | ? | ? | ? | ? | ? | ? | ? | |
| Microbial Products | LPS | ↑ Hayashi et al., | ↓/↑ Fan and Malik, | ↑ Hayashi et al., | ↑ Fittschen et al., | ↑ Hazeldine et al., | ↓ Klein et al., | ↑ Cassatella, |
| LAMs | ? | No change Fietta et al., | No change Fietta et al., | ↑ Faldt et al., | ? | ? | ? | |
| Lipopeptide | ↑ Hayashi et al., | ↓/↑ Aomatsu et al., | ↑ Hayashi et al., | ↑/↓ (Whitmore et al., | ? | Minimal effect Sabroe et al., | ↑/↓ Whitmore et al., | |
| Flagellin | ↑ Hayashi et al., | ↓ Hayashi et al., | ↑ Hayashi et al., | ? | ? | No change/↓ Francois et al., | ↑/↓ Hayashi et al., | |
| Others | ATP | ? | ↑ Ding et al., | ? | ↑ Aziz et al., | ? | ? | ? |
| Substance P | ↑ Dianzani et al., | ↑ Marasco et al., | ? | ↑ Marasco et al., | ? | ↓ Bockmann et al., | ↑ Perianin et al., | |
| CL097, CL075 | ? | ? | ? | ↑ Makni-Maalej et al., | ? | ? | ? | |
| Adhesion | ↑ Kasorn et al., | ↑ Xu and Hakansson, | ? | ↓ Mayadas and Cullere, | ↑ Steadman et al., | |||
Table .